"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 5 | 5 |
| 2001 | 4 | 9 | 13 |
| 2002 | 2 | 3 | 5 |
| 2003 | 0 | 7 | 7 |
| 2004 | 2 | 9 | 11 |
| 2005 | 0 | 10 | 10 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 13 | 13 |
| 2008 | 2 | 15 | 17 |
| 2009 | 0 | 16 | 16 |
| 2010 | 0 | 17 | 17 |
| 2011 | 0 | 19 | 19 |
| 2012 | 0 | 13 | 13 |
| 2013 | 0 | 12 | 12 |
| 2014 | 5 | 5 | 10 |
| 2015 | 1 | 13 | 14 |
| 2016 | 2 | 14 | 16 |
| 2017 | 3 | 14 | 17 |
| 2018 | 0 | 23 | 23 |
| 2019 | 7 | 15 | 22 |
| 2020 | 4 | 4 | 8 |
| 2021 | 3 | 9 | 12 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 15 | 15 |
| 2025 | 1 | 10 | 11 |
| 2026 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
-
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. Eur J Cardiothorac Surg. 2026 03 10; 68(3).
-
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 02; 394(13):1257-1269.
-
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
-
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 12 01; 8(12):e2549109.
-
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Nov 01; 117(11):2388-2393.
-
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. Ann Oncol. 2025 11; 36(11):1356-1365.
-
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 09; 23(9):403-418.